0      0

2020 ISPE Biopharmaceutical Manufacturing Virtual Conference


Challenges and Opportunities in the Manufacturing of New Treatment Modalities


Jun 1, 2020 9:00am ‐ Jun 1, 2020 10:30am

Description

This year, the 2020 ISPE Biopharmaceutical Manufacturing Conference will focus on advances in manufacturing, facilities, and analytics important to bring new therapies to patients. Now more than ever, manufacturing is on the critical path as many new treatments in the area of personalized medicines and individualized batch production present the challenge to bring these medicines through rapid development, reliable manufacturing, and availability to patients a pace with the advances clinical research is bringing to address unmet needs. At the same time, biosimilars are advancing with the opportunity to provide more access to medicines. In this opening session, we will hear an important regulatory perspective from FDA on gene therapy drug development and a reflection from industry on 10 years on Biosimilars.

Moderator(s):

  • Joseph Famulare, Conference Chair, VP Global Compliance & External Collaboration, Genentech, A Member of the Roche Group

Speaker(s):

  • Tim Howard, PE, CPIP, Interim CEO & President, ISPE
  • Tom Hartman, CEO & President, ISPE
  • Eric Felz, Associate Director Validation, Takeda Pharmaceutical Company
  • Carol Lynch, President, Head-North America, Sandoz US
  • Wilson Bryan, MD, Director, Office of Tissues and Advanced Therapies, FDA/CBER, CBER/FDA

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content